)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Genomtec
Genomtec (GMT) investor relations material
Genomtec Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary1 Jun, 2026
Executive summary
Group operates in biotechnology and medical device R&D, focusing on mobile diagnostic platforms and infectious disease tests.
No changes in group structure or ownership during the reporting period.
Shares are publicly traded since February 2023.
Financial highlights
Consolidated revenue from sales: 16k PLN, up from 5k PLN year-over-year.
Consolidated net loss: (2,196)k PLN, improved from (3,205)k PLN year-over-year.
Cash and equivalents at period end: 2,605k PLN, down from 4,722k PLN at year-end 2025.
Operating cash flow: (1,840)k PLN, improved from (3,357)k PLN year-over-year.
No dividend paid or declared.
Outlook and guidance
Ongoing R&D funded by equity, grants, and planned new share issues.
2026 grant inflows expected at approx. 15.6m PLN.
Further share issues may be needed to finance commercialization.
Profitability expected after commercialization of developed technologies.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Genomtec
- Patent expansion, cost cuts, and narrowed loss set the stage for commercialization in 2026.GMT
Q4 202530 Apr 2026 - Genomtec accelerates M&A, slashes production costs, and strengthens its position in diagnostics.GMTInvestor Update23 Apr 2026
- Net loss widened to PLN -11.2m as R&D continued, with equity raises ensuring 12+ months liquidity.GMTQ4 202416 Apr 2026
- Net loss persists as R&D spending rises; commercialization and funding remain critical.GMTQ3 202529 Nov 2025
- Rapid genetic diagnostics, strong IP, and robust funding drive growth and M&A momentum.GMTInvestor Presentation13 Nov 2025
- Net loss deepened to PLN 6.6M as R&D spending rose; commercialization still ahead.GMTQ2 202529 Sep 2025
- Losses persist as Genomtec advances R&D, secures funding, and pursues M&A for commercialisation.GMTQ3 202413 Jun 2025
- Net loss widened to PLN 6.0 million in H1 2024 as Genomtec advanced R&D and raised new capital.GMTQ2 202413 Jun 2025
- Genomtec's Q1 2025 loss widened as R&D ramped up, with commercialization still pending.GMTQ1 20256 Jun 2025
Next Genomtec earnings date
Q2 202630 Sep, 2026
Genomtec
Next Genomtec earnings date
Q2 202630 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage